Evonik invests US$100 million to upgrade Tippecanoe Labs in Lafayette, Indiana
- US$100 million investment to modernize Tippecanoe Labs over the next five years.
- Site upgrades include large reactors, automation, ergonomics improvements and Next Generation Technologies.
- Tippecanoe Labs is one of the world’s largest API facilities, with more than 650 employees and the industry’s largest high‑potency API operation.
- Purpose is to expand U.S.-based CDMO drug substance capacity, handle rising API complexity, and secure local jobs.
Investment and timeline
Evonik will invest US$100 million over the next five years to modernize key equipment at its Tippecanoe Labs site in Lafayette, Indiana, enhancing reliability and efficiency across the facility.
Scope of upgrades
Planned work covers large reactors and other critical systems, enabling greater automation, improved ergonomics and energy‑efficient processes described as Next Generation Technologies.
Strategic rationale
The upgrades are intended to strengthen Evonik’s U.S. drug substance CDMO footprint as part of a global asset balancing strategy across North America, Europe and Asia, and to meet growing demand for U.S.-based contract manufacturing services.
Capabilities and local impact
Tippecanoe Labs, acquired from Eli Lilly in 2010, is a major API and excipients site and houses the company’s largest high‑potency API operation with more than 650 employees; Evonik says the investment will help secure jobs, support the local economy and enable work on increasingly complex molecules for critical indications.
Source: Evonik
